קורסודיל שטיפת פה ישראל - עברית - Ministry of Health

קורסודיל שטיפת פה

gsk consumer healthcare, israel ltd - chlorhexidine digluconate - תמיסה - chlorhexidine digluconate 0.2 %w/v - chlorhexidine - chlorhexidine - antibacterial solution for the disinfection of the mouth.1. as an aid to maintaining oral hygiene.2. as an aid in the treatment and prevention of gingivitis.3. inhibition of formation of dental plaque.4. for use in aphtous ulceration and oral candidal infections (eg denture stomatitis and thrush).5. for use in a post- periodontal surgery or treatment regimen to promote gingival healing.

ונופר ישראל - עברית - Ministry of Health

ונופר

cts ltd - ferrous as iron iii hydroxide sucrose complex - תמיסה להזרקה - ferrous as iron iii hydroxide sucrose complex 20 mg/ml - iron-sorbitol-citric acid complex - iron-sorbitol-citric acid complex - severe iron deficiency only when oral administration has been found impossible. in cases of gastro-intestinal malobsorption which rules out oral therapy, patients on dialysis treated with erythropoietin.

ונופר ישראל - עברית - Ministry of Health

ונופר

cts ltd - ferrous as iron iii hydroxide sucrose complex - תמיסה להזרקה - ferrous as iron iii hydroxide sucrose complex 100 mg / 5 ml - iron-sorbitol-citric acid complex - iron-sorbitol-citric acid complex - severe iron deficiency only when oral administration has been found impossible. in cases of gastro-intestinal malobsorption which rules out oral therapy, patients on dialysis treated with erythropoietin.

קובאלטרי IU 1000 ישראל - עברית - Ministry of Health

קובאלטרי iu 1000

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 1000 iu - coagulation factor viii

קובאלטרי IU 2000 ישראל - עברית - Ministry of Health

קובאלטרי iu 2000

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 2000 iu - coagulation factor viii

קובאלטרי IU 250 ישראל - עברית - Ministry of Health

קובאלטרי iu 250

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 250 iu - coagulation factor viii

קובאלטרי IU 500 ישראל - עברית - Ministry of Health

קובאלטרי iu 500

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 500 iu - coagulation factor viii

פוסאלאן פעם בשבוע 70 מג ישראל - עברית - Ministry of Health

פוסאלאן פעם בשבוע 70 מג

organon pharma israel ltd., israel - alendronate as sodium - טבליה - alendronate as sodium 70 mg - alendronic acid - alendronic acid - fosalan is indicated for the treatment of osteoporosis in postmenopausal women to prevent fractures, including those of the hip and spine (vertebral compression fractures). treatment to increase bone mass in men with osteoporosis.

אנראביק % 10 וטרינרי ישראל - עברית - Ministry of Health

אנראביק % 10 וטרינרי

abic veterinary products ltd - enrofloxacin - תמיסה - enrofloxacin 100 mg/ml

אפיניטור 5 מג ישראל - עברית - Ministry of Health

אפיניטור 5 מג

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*